Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
ORIGINAL ARTICLE

High serum nitrates levels in non-survivor COVID-19 patients

L. Lorente\textsuperscript{a,*}, F. Gómez-Bernal\textsuperscript{b}, M.M. Martín\textsuperscript{c}, J.A. Navarro-Gonzálvez\textsuperscript{b}, M. Argueso\textsuperscript{d}, A. Perez\textsuperscript{e}, L. Ramos-Gómez\textsuperscript{f}, J. Solé-Violán\textsuperscript{g}, J.A. Marcos y Ramos\textsuperscript{h}, N. Ojeda\textsuperscript{i}, A. Jiménez\textsuperscript{j}, Working Group on COVID-19 Canary ICU

\textsuperscript{a} Intensive Care Unit, Hospital Universitario de Canarias, La Laguna, Santa Cruz de Tenerife, Spain
\textsuperscript{b} Laboratory Department, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain
\textsuperscript{c} Intensive Care Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
\textsuperscript{d} Intensive Care Unit, Complejo Hospitalario Universitario Insular, Las Palmas de Gran Canaria, Spain
\textsuperscript{e} Internal Intensive Care Unit, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain
\textsuperscript{f} Intensive Care Unit, Hospital General La Palma, Breña Alta, Santa Cruz de Tenerife, Spain
\textsuperscript{g} Intensive Care Unit, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain
\textsuperscript{h} Intensive Care Unit, Hospital Doctor José Molina Orosa, Arrecife, Las Palmas, Spain
\textsuperscript{i} Department of Anesthesiology, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain
\textsuperscript{j} Research Unit, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain

Received 15 September 2020; accepted 25 October 2020

KEYWORDS
Serum nitrate levels; COVID-19; Patients; Mortality; Prognosis

Abstract

Objective: Higher blood nitrate and nitrite levels have been found in coronavirus disease 2019 (COVID-19) patients than in healthy subjects. The present study explores the potential association between serum nitrate levels and mortality in COVID-19 patients.

Design: A prospective observation study was carried out.

Setting: Eight Intensive Care Units (ICUs) from 6 hospitals in the Canary Islands (Spain).

Patients: COVID-19 patients admitted to the ICU.

Interventions: Determination of serum nitrate levels at ICU admission.

Main variable of interest: Mortality at 30 days.

Results: Non-surviving (n=11) compared to surviving patients (n=42) showed higher APACHE-II (p=0.001) and SOFA scores (p=0.004), and higher serum nitrate levels (p=0.001). Logistic regression analyses showed serum nitrate levels to be associated to 30-day mortality after controlling for SOFA (OR=1.021; 95\%CI=1.006–1.036; p=0.01) or APACHE-II (OR=1.023; 95\%CI=1.006–1.039; p=0.01).

\* Corresponding author.
E-mail address: lorentemartin@msn.com (L. Lorente).
Introduction

Coronavirus disease 2019 (COVID-19), an emerging health threat in the world, is the disease produced by the novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was detected for the first time in Wuhan (China) in December 2019. To September 15 of 2020 approximately had 29,459,649 confirmed cases and 932,997 deaths (3.2%) from COVID-19. Several factors have been associated with higher death as age, some comorbidities (cardiovascular diseases, arterial hypertension, chronic obstructive pulmonary disease, smoking, diabetes mellitus or cerebrovascular diseases), some blood biomarkers (of kidney dysfunction, inflammation, cardiac injury, muscle injury, liver dysfunction and coagulation alterations), and some clinical data as the appearance of acute respiratory distress syndrome (ARDS). 3–8

In sepsis, nitric oxide synthesis is dysregulated with exaggerated production leading to cardiovascular dysfunction, bioenergetic failure and cellular toxicity. 9–16 Nitric oxide is a very unstable and short half-life gas that breaks rapidly to the stable products as nitrate and nitrite. 17,18 Higher blood nitrate and nitrite levels has been found in patients with higher sepsis severity, 19–23 and in non-survivor than in survivor septic patients. 24 Increased blood nitrate and nitrite levels has been found in COVID-19 patients than in healthy subjects; 25 however, we have not found data about serum nitrate levels and prognosis of COVID-19 patients. Thus, the...
objective of this study was to explore the potential association between serum nitrate levels and mortality of COVID-19 patients.

Methods

Design and subjects

Eight Intensive Care Units from 6 hospitals of Canary Islands (Spain) participated in this prospective and observational study. The patients were recruited during March and April of 2020. The Ethics Committee (Protocol code CHUC-2020-26) from each hospital approved the protocol study. Due to the context of the rapid emergence of this infectious disease and the prohibition of patient visits by the Government of Spain due to the public health outbreak policy, and due to that data were prospectively collected, the requirement of written informed consent for participate in the study was waived.

Patients admitted to the ICU during April of 2020 with laboratory-confirmed COVID-19 by an assay of real time fluorescence reverse transcription-polymerase chain reaction (RT-PCR) from nasopharyngeal swab sample or a bronchial aspirate were included.

Determination of serum nitrate levels

We collected blood samples at ICU admission in serum separator tubes and serum was stored immediately at −80 °C until to the end of recruitment. All determinations of serum nitrate concentrations were performed blindly to clinical data in the same Laboratory Department. Nitrate determination was performed following the procedure described by Navarro-Gonzálvez et al.25 with some modifications. The measurement was made on a Cobas C 501 analyzer (Roche Diagnostics). Each of the 5 batches into which the samples were divided for analysis was processed together with five calibrators (concentrations 0, 5, 20, 40, 80 mM) processed analogously to the samples, as well as 2 controls (of concentrations 20.5 mM and 71 mM, from which a coefficient of variation of 9.5% and 5.1% respectively was obtained).

Variables recorded

Data patients were anonymized. In respect to demographic and clinical characteristics, we recorded the following data: sex, body max index, age, and history of chronic renal failure, diabetes mellitus, chronic obstructive pulmonary disease (COPD), chronic liver disease, smoking cessation, active smoking, ischemic heart disease, arterial hypertension, steroid agents, hematological tumor, human immunodeficiency virus (HIV) and solid tumor. Besides, we recorded temperature, chest radiography findings, Sepsis-related Organ Failure Assessment [SOFA] score,26 Acute Physiology and Chronic Health Evaluation (APACHE-II) score,27 and the development of septic shock28 and ARDS.29

Regarding to laboratory data at ICU admission, we recorded glucose, lactic acid, creatinine, sodium, protein, albumin, creatine kinase, bilirubin, alanine transaminase, aspartate transaminase, gamma-glutamyl transpeptidase, alkaline phosphatase, lactate dehydrogenase, procalsitonin, C-reactive protein, ferritin, N-terminal prohormone of brain natriuretic peptide (NTproBNP), interleukin-6, hematocrit, hemoglobin, white blood cell, lymphocytes, neutrophils, monocytes, basophils, eosinophils, platelets, activated partial thromboplastin time (aPTT), international normalized ratio (INR), d-dimer, fibrinogen, pressure of arterial oxygen (PaO2), fraction inspired of oxygen (FiO2).

In respect to ICU treatment, we recorded prone position, neuromuscular blockers, respiratory support, hydrocortisone, lopinavir/ritonavir, interferon, tocilizumab, steroid agents, vasopressors, and intermittent and continuous renal replacement therapy. Finally, we considered survival at 30 days as our endpoint study.

Statistical methods

Medians (percentile 25–75), frequencies (percentages), Mann–Whitney U test and chi-square test were used to describe and compare continuous and categorical variables between surviving and non-surviving patient groups. We tested the ability of serum nitrate levels, SOFA and APACHE-II to predict mortality using receiver operating characteristic (ROC) analysis, and areas under curves were compared with the method of DeLong et al.30 We constructed Kaplan–Meier 30-day survival curves using serum nitrates concentrations ≤68.4 μmol/L and >68.4 μmol/L (level point selected in basis to Youden J index), and curves were compared with log-rank test. We performed logistic regression analyses to determine the possible association between serum nitrate levels and 30-day mortality after to control by SOFA or APACHE-II. We constructed two models with only two predictor variables in each model due to the number of death patients was 11, and Odds Ratio and its 95% confidence intervals were reported. We used Spearman’s rank correlation coefficient to test association between continuous variables. A point p < 0.05 was used to consider significant differences. Statistical analyses were carried out with SPSS 17.0 (SPSS Inc., Chicago, IL, USA).

Results

A total of 53 patients were included, all admitted in ICU with respiratory insufficiency, with SOFA of 5.7 ± 2.5 and APACHE-II of 13.4 ± 6.5. Of them, 42 (79.2%) received invasive mechanical ventilation, 40 (75.5%) vasopressors, and 8 (15.1%) renal replacement therapy. We found that non-surviving (n = 11) compared to surviving patients (n = 42) showed higher temperature (p = 0.03), septic shock (p = 0.048), APACHE-II (p < 0.001) and SOFA (p = 0.004) (Table 1). In addition, non-surviving showed higher serum nitrate levels (p = 0.001) and NTproBNP (p = 0.04), and lower platelet count (p = 0.02) (Table 2). Besides, non-surviving patients received more frequently CRRT (p = 0.048) and vasopressors (p = 0.047) during its ICU stay (Table 3).

Logistic regression analyses showed that serum nitrate levels were associated with 30-day mortality after controlling for SOFA (OR = 1.021; 95% CI = 1.006–1.036; p = 0.01), APACHE-II (OR = 1.023; 95% CI = 1.006–1.041;
Table 1  Demographic and clinical data of non-surviving and surviving patients.

|                        | Survivors (n = 42) | Non-survivors (n = 11) | p value |
|------------------------|--------------------|------------------------|---------|
| Gender female – n (%)  | 27 (64.3)          | 7 (63.6)               | 0.99    |
| Age (years) – median (p 25–75) | 65 (51–70)       | 70 (59–75)             | 0.10    |
| Body max index (kg/m²) – median (p 25–75) | 28.1 (24.8–32.4) | 27.1 (23.0–30.2)       | 0.29    |
| Diabetes mellitus – n (%) | 12 (28.6)      | 3 (27.3)               | 0.99    |
| COPD – n (%)            | 5 (11.9)           | 3 (27.3)               | 0.34    |
| Ischemic heart disease – n (%) | 1 (2.4)      | 1 (9.1)                | 0.38    |
| Smoking – n (%)         | 2 (4.8)            | 2 (18.2)               | 0.19    |
| Arterial hypertension – n (%) | 16 (38.1)    | 6 (54.5)               | 0.49    |
| Steroid agents – n (%)  | 1 (2.4)            | 2 (18.2)               | 0.11    |
| Temperature ( °C) – median (p 25–75) | 37.0 (36.0–37.5) | 35.2 (34.1–36.7)       | 0.03    |
| Chest radiography findings – n (%) | 5 (11.9)    | 1 (9.1)                |         |
| ARDS – n (%)            | 36 (85.7)          | 9 (81.8)               | 0.67    |
| Septic shock – n (%)    | 4 (9.5)            | 4 (36.4)               | 0.048   |
| APACHE-II score – median (p 25–75) | 12 (7–15)     | 18 (16–20)             | <0.001  |
| SOFA score – median (p 25–75) | 5 (3–7)        | 8 (5–9)                | 0.004   |

COPD = Chronic Obstructive Pulmonary Disease; APACHE = Acute Physiology and Chronic Health Evaluation; SOFA = Sepsis-related Organ Failure Assessment; ARDS = acute respiratory distress syndrome.

Table 2  Laboratory data at ICU admission of non-surviving and surviving patients.

|                          | Survivors (n = 42) | Non-survivors (n = 11) | p value |
|--------------------------|--------------------|------------------------|---------|
| Serum nitrates levels (µmol/L) – median (p 25–75) | 20 (15–43)        | 86 (40–224)            | 0.001   |
| Lactic acid (mmol/L) – median (p 25–75) | 1.33 (1.09–1.80) | 1.60 (1.30–2.20)       | 0.11    |
| Sodium (mEq/L) – median (p 25–75) | 138 (134–141)     | 140 (135–144)          | 0.20    |
| Creatinine (mg/dl) – median (p 25–75) | 0.87 (0.68–1.03) | 1.07 (0.72–1.73)       | 0.23    |
| Protein (g/L) – median (p 25–75) | 6.4 (5.8–7.1)    | 6.0 (5.6–7.0)          | 0.60    |
| C-reactive protein (mg/gl) – median (p 25–75) | 20 (10–76)       | 24 (18–67)             | 0.34    |
| Procalcitonin (ng/ml) – median (p 25–75) | 0.17 (0.08–0.48) | 0.58 (0.06–0.76)       | 0.49    |
| Ferritin (ng/ml) – median (p 25–75) | 1039 (653–1817) | 1383 (859–2761)        | 0.50    |
| NTproBNP (pg/ml) – median (p 25–75) | 451 (137–1379)   | 5953 (5334–6371)       | 0.04    |
| Interleukin-6 (pg/ml) – median (p 25–75) | 50 (6–179)      | 61 (24–140)            | 0.77    |
| Hemoglobin (g/dl) – median (p 25–75) | 12.8 (11.7–14.4) | 12.8 (11.0–15.0)       | 0.95    |
| White blood cell – median10³/mm³ (p 25–75) | 7.7 (6.0–11.6) | 7.9 (5.3–13.1)         | 0.95    |
| Platelets – median10³/mm³ (p 25–75) | 246 (173–383)    | 158 (108–278)          | 0.02    |
| INR – median (p 25–75) | 1.17 (1.06–1.36) | 1.18 (1.02–1.32)       | 0.83    |
| aPTT (seconds) – median (p 25–75) | 27 (25–32)      | 30 (23–36)             | 0.52    |
| Fibrinogen (mg/dl) – median (p 25–75) | 711 (506–829)  | 699 (600–910)          | 0.49    |
| D-dimer (ng/mL) – median (p 25–75) | 1102 (744–2202) | 3516 (682–21480)       | 0.21    |
| PaO2/FIO2 ratio – median (p 25–75) | 133 (103–201)   | 111 (100–140)          | 0.30    |

NTproBNP = N-terminal prohormone of brain natriuretic peptide; INR = International normalized ratio; aPTT = Activated partial thromboplastin time; PaO2 = pressure of arterial oxygen; FIO2 = fraction inspired oxygen.

p = 0.01) or serum creatinine concentrations (OR = 1.022; 95% CI = 1.007–1.038; p = 0.004 (Table 4).

We did not find differences in the area under curve (AUC) for mortality prediction by serum nitrate levels (AUC = 83%; 95% CI = 73–92%; p < 0.001) (Fig. 1), APACHE II (AUC = 85%; 95% CI = 75–96%; p < 0.001) and SOFA (AUC = 78%; 95% CI = 63–92%; p = 0.005).

The selected point of serum nitrates levels > 68.4 µmol/L for mortality prediction had 64% of sensitivity (31–89%), 95% of specificity (84–99%), 13.4 of positive likelihood ratio (3.2–55.5), 0.4 of negative likelihood ratio (0.2–0.8), 78% of positive predictive value (46–94%) and 91% of negative predictive value (82–96%). In Kaplan–Meier analysis we found that patients with serum nitrates levels > 68.4 µmol/L...
Table 3  Treatment data in ICU of non-surviving and surviving patients.

|                          | Survivors (n = 42) | Non-survivors (n = 11) | p value |
|--------------------------|--------------------|------------------------|---------|
| **Respiratory support – n (%)** |                    |                        |         |
| Conventional oxygen therapy | 4 (9.5)            | 0                      | 0.30    |
| High-flow nasal cannula    | 4 (9.5)            | 0                      |         |
| Non-invasive mechanical ventilation | 3 (7.1)       | 0                      |         |
| Invasive mechanical ventilation | 31 (73.8)   | 11 (100)               |         |
| **Neuromuscular blockers – n (%)** |                    |                        | 0.99    |
| Prone position – n (%)      | 26 (61.9)          | 7 (63.6)               |         |
| Lopinavir/Ritonavir – n (%) | 13 (31.0)          | 4 (36.4)               | 0.73    |
| Hydroxychloroquine – n (%) | 39 (92.9)          | 10 (90.9)              | 0.99    |
| Interferon Beta 1-B – n (%) | 39 (92.9)          | 11 (100)               | 0.99    |
| Tocilizumab – n (%)         | 26 (61.9)          | 7 (63.6)               | 0.99    |
| Steroid agents – n (%)      | 15 (35.7)          | 6 (54.5)               | 0.31    |
| Intermittent renal replacement therapy – n (%) | 31 (73.8) | 9 (81.8) | 0.71 |
| Continuous renal replacement therapy – n (%) | 0                  | 0                      | –       |
| Vasopressors – n (%)        | 29 (69.0)          | 11 (100)               | 0.047   |

Table 4  Multiple logistic regression analyses to predict mortality at 30 days.

|                          | Odds ratio | 95% confidence interval | p-Value |
|--------------------------|------------|-------------------------|---------|
| **Model 1:**             |            |                         |         |
| Serum nitrates levels (µmol/L) | 1.021       | 1.006–1.036              | 0.01    |
| SOFA score (points)      | 1.496      | 1.022–2.189              | 0.04    |
| **Model 2:**             |            |                         |         |
| Serum nitrates levels (µmol/L) | 1.023       | 1.006–1.041              | 0.01    |
| APACHE-II (points)       | 1.336      | 1.076–1.657              | 0.01    |
| **Model 3:**             |            |                         |         |
| Serum nitrates levels (µmol/L) | 1.022       | 1.007–1.038              | 0.004   |
| Creatinine (mg/dl)       | 1.093      | 0.948–1.260              | 0.22    |

SOFA = Sepsis-related Organ Failure Assessment; APACHE = Acute Physiology and Chronic Health Evaluation.

Figure 1  Receiver operating characteristic analysis using serum nitrates concentration for prediction of mortality at 30 days.

had a higher mortality rate (Hazard ratio = 138.8; 95% CI = 22.3–863.9; p < 0.001) (Fig. 2).

We did not find significant differences in serum nitrate levels between patients with and without septic shock.

Figure 2  Survival curves at 30 days using serum nitrates concentrations lower or equal vs higher than 68.4 µmol/L.
(p = 0.05). We did not find a significant association of serum nitrate levels with norepinephrine dosage at the time of patient inclusion (n = 53; rho = 0.24; p = 0.09) and NTproBNP (n = 20; rho = 0.30; p = 0.20).

Discussion

To our knowledge, our series is the first one reporting serum nitrate levels in COVID-19 patients and the main new finding was the association between serum nitrate levels and mortality controlling for SOFA or APACHE-II.

Serum nitrite and nitrate are the stable end products of nitric oxide. Increased serum levels of these metabolites could be due to increased nitric oxide production and/or decreased elimination of serum nitrite and nitrate due to alterations in renal function. We have not found significant differences between survivor and non-survivor patients in renal function at ICU admission when were obtained blood samples for the determination of serum nitrate levels. In addition, we have found an association between serum nitrate levels and mortality after to control for serum creatinine concentrations. Thus, it is possible that those higher serum nitrate levels from non-survivor patients could be due mainly to a higher nitric oxide production.

Besides of serum nitrate levels, other variables with significant difference between non-surviving and surviving patients were septic shock, APACHE-II, SOFA, NTproBNP, and platelet count. Other factors that have been associated with higher death as age, several comorbidities, blood biomarkers of inflammation and coagulation alterations; however, in our series no other significant differences were found possibly due to the small sample size of our study. In addition, the prevalence of symptomatic COVID-19 has been found to be higher in men than in women; however, in our series had more women possibly due to the small sample size of our study, although no had significant differences in mortality according the sex.

Increased nitric oxide production occurs in sepsis due to increased mRNA expression of the enzyme namely inducible nitric oxide synthase (iNOS) in different cells as endothelial cells, platelets, macrophages and cardiac myocytes after exposure to bacterial lipopolysaccharide. This increase of nitric oxide contribute to cardiovascular dysfunction (vasodilation, hyporeactivity to vasopressors and negative inotropic effect), bioenergetic failure (inhibition of mitochondrial respiration due to that alter the function of the mitochondrial respiratory complex IV interrupting the normal transport of electrons leading to decreased adenosine triphosphate production) and cellular toxicity (activation of intrinsic apoptosis pathway trough the opening of mitochondrial transition pores allowing the transportation of cytochrome c from the mitochondria into the cytosol, which activate caspase-9 and that activate caspases 3 that leads to death cell by apoptosis). In our study, we found a trend to a higher serum nitrate levels in patients with septic shock, and a trend to positive associations of serum nitrate levels with norepinephrine dosage at the time of patient inclusion and with blood NTproBNP concentrations; although it is possible that the sample size contribute in the absence of significant differences. In addition, we have not studied mitochondrial respiratory complex and apoptosis, and those were some limitations of our study. We think that this association between high serum nitrate levels and high COVID-19 patients mortality found in our study could be due to a higher nitric oxide production which lead to cardiovascular dysfunction, bioenergetic failure and cellular toxicity and all this can contribute to organ dysfunction and finally the death of the patients. Our novel findings about higher serum nitrate levels in non-survivor than in survivor COVID-19 patients are in line with those found in septic patients.

In a study of pulmonary autopsy specimens from patients who died from Covid-19 or from influenza A(H1N1) infection or from uninfected patients was found higher angiogenesis in lungs from patients with Covid-19. In addition, nitric oxide has been associated with angiogenesis in different diseases as cancer or chronic liver diseases. Thus, it is possible that if we had studied pulmonary autopsy specimens and serum nitrate levels during patient evolution, we would have observed in non-survivor patients persistently higher serum nitrate levels and a great angiogenesis in autopsies. However, those were other limitations of our study.

Other limitation of our study was that the limited number of deaths prevented that more variables were included in the same regression model. However, a strength of the study was that the association between serum nitrate levels and mortality remained after controlling for SOFA or APACHE-II. Another interesting finding of our study was that the capacity for mortality prediction provided by serum nitrate levels was not different that those of SOFA and APACHE-II. We think that the practical usefulness of our study lies in the fact that serum nitrate levels, with an easy and cheap determination, could help to clinicians in the estimation of prognosis in COVID-19 patients.

In recent years, different approaches to modulate nitric oxide activity in septic patients (agents that reducing nitric oxide production inhibiting iNOS or increasing nitric oxide elimination acting as scavengers) have improved systemic vascular resistance and blood pressure in patients with septic shock without obtain a reduction in mortality rate. The development of other pharmacological strategies to reduce iNOS to decrease nitric oxide production could improve the prognosis of those patients. Recently, the inhibition of iNOS by amagatin has attenuated vascular dysfunction and mortality rate in rat endotoxemic model. In addition, in a small study were administered three antioxidants (methylene blue, vitamin C and N-acetyl cysteine) to five COVID-19 patients and serum nitrate levels decreased after treatment. Other therapeutic aspect in COVID-19 patients is the potential use of inhaled nitric oxide due to its vasodilation effect to reverse pulmonary hypertension and due to its potential antiviral activity against SARS-CoV-2 infection.

Conclusions

The main new finding of our study was the association between serum nitrate levels and mortality in COVID-19 patients controlling for SOFA or APACHE-II, but larger studies are needed to confirm this result.
Authors’ contributions

LLo conceived, designed and coordinated the study, participated in acquisition and interpretation of data, and drafted the manuscript.

MM, MA, AP, LRG, JSV, JAMR and NO participated in acquisition of data.

FGB and JANG carried out the determinations of serum nitrates levels.

AJ participated in the interpretation of data.

All authors revised the manuscript critically for important intellectual content and made the final approval of the version to be published.

Funding

This study was supported by a grant from Instituto de Salud Carlos III (PI-18-00500) (Madrid, Spain) and co-financed with Fondo Europeo de Desarrollo Regional (FEDER).

Conflicts of interest

The authors declare that they have no competing interests.

Acknowledgments

Investigators of Working Group of COVID-19 Canary ICU: Leonardo Lorente, Fuensanta Gómez-Bernal, José Antonio Navarro-González, Alina Perez, Alejandro Jiménez, Alexandra Pérez-Llombet, Luis Uribe, Lourdes González, Rocio Alvarez, (Hospital Universitario de Canarias. La Laguna. Tenerife. Spain); María M. Martin, Julia Alcoba-Flórez, Miguel Angel Rodriguez, Albano Estupiñan (Hospital Universitario Nuestra Señora de Candelaria. Santa Cruz de Tenerife. Spain); Mónica Argueso, Juan J. Cáceres, Marta Riaño-Ruiz, Juan Guillermo O’Campo, Paula Vega, Lucia Gonzalez (Hospital Insular. Las Palmas de Gran Canaria. Spain); Jordi Solé-Violán, Nazario Ojeda, Sergio López, Aurelio Rodríguez-Pérez, Casimira Dominguez (Hospital Universitario Dr. Negrín. Las Palmas de Gran Canaria. Spain); José Alberto Marcos y Ramos, Maria F. Zapata, Tamara Cantera (Hospital Doctor José Molina Orosa. Lanzarote. Spain); Luis Ramos-Gómez, Raquel Ortiz-López, Leopoldo Martin Martin (Hospital General La Palma. La Palma. Spain).

References

1. World Meters. Coronavirus disease (COVID-19). https://www.worldometers.info/coronavirus/coronavirus-cases [assessed 15.09.20].
2. World Heart Organization. Coronavirus disease (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [assessed 15.09.20].
3. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; http://dx.doi.org/10.1007/s00134-020-05991-x [Epub ahead of print].
4. Liu W, Tao ZW, Lei W, Ming-Li Y, Kui L, Ling Z, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Eng). 2020; http://dx.doi.org/10.1097/CMA.0000000000000775 [Epub ahead of print].
5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan China: a retrospective cohort study. Lancet. 2020;395:1054–62.
6. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan China. JAMA Intern Med. 2020; http://dx.doi.org/10.1001/jamainternmed.2020.0994 [Epub ahead of print].
7. Henry BM, de Oliveira MHS, Benoist S, Pibani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020 [Epub ahead of print].
8. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55:2000524, http://dx.doi.org/10.1183/13993003.00524-2020. Print 2020 May.
9. Habibana R, Choi I, Cho HJ, Kim D, Lee K, Jeong I. Sepsis-induced cardiac dysfunction: a review of pathophysiology. Acute Care. 2020;35:57–66.
10. Sharawy N, Lehmann C. Molecular mechanisms by which iNOS uncoupling can induce cardiovascular dysfunction during sepsis: role of posttranslational modifications (PTMs). Life Sci. 2020;255:117821.
11. Lin Y, Xu Y, Zhang Z. Sepsis-induced myocardial dysfunction (SIMD): the pathophysiological mechanisms and therapeutic strategies targeting mitochondria [published online ahead of print, 2020 Apr 24]. Inflammation. 2020;10, http://dx.doi.org/10.1007/s10753-020-01233-w.
12. Kazune S, Piebalga A, Strike E, Vanags I. Impaired vascular reactivity in sepsis – a systematic review with meta-analysis. Arch Med Sci Atheroscler Dis. 2019;4:e151–61.
13. Lambden S. Bench to bedside review: therapeutic modulation of nitric oxide in sepsis-an update. Intensive Care Med Exp. 2019;7:64.
14. Mantzarlis K, Tsołaki V, Zakynthinos E. Role of oxidative stress and mitochondrial dysfunction in sepsis and potential therapies. Oxid Med Cell Longev. 2017;2017:5985209.
15. Duvigneau JC, Kozlov AV. Pathological impact of the interaction of NO and CO with mitochondria in critical care diseases. Front Med (Lausanne). 2017;4:223.
16. Durand A, Dubucq T, Dekeyser T, Niviere R, Howsman S, Favory R, et al. Involvement of mitochondrial disorders in septic cardiomyopathy. Oxid Med Cell Longev. 2017;2017:4076348.
17. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524–6.
18. Wennmalm A, Benthin G, Edlund A, Jungersten L, Kiefer Jensen N, Lundin S, et al. Metabolism and excretion of nitric oxide in humans: an experimental and clinical study. Circ Res. 1993;73:1121–7.
19. Pereira FH, Batalhão ME, Cárno EC. Correlation between blood temperature, blood pressure and plasmatic nitric oxide in septic patients. Rev Lat Am Enfermagem. 2014;22:123–8.
20. Kothari N, Bogra J, Kohli M, Malik A, Kothari D, Srivastava S, et al. Role of active nitrogen molecules in progression of septic shock. Acta Anaesthesiol Scand. 2012;56:307–15.
21. Novotny AR, Emmanuel K, Maier S, Alexandra Westerholt, Heike Weighardt, Josef Stadler, et al. Cytochrome P450 activity mirrors nitric oxide levels in postoperative sepsis: predictive indicators of lethal outcome. Surgery. 2007;141:376–84.
22. Mitaka C, Hirata Y, Yokoyama K, Wakimoto H, Hirokawa M, Nosaka T, et al. Relationships of circulating nitrite/nitrate levels to severity and multiple organ dysfunction syndrome in systemic inflammatory response syndrome. Shock. 2003;19:305–9.

23. Ho JT, Chapman MJ, O’Connor S, Lam S, Edwards J, Ludbrook G, et al. Characteristics of plasma NOx levels in severe sepsis: high interindividual variability and correlation with illness severity, but lack of correlation with cortisol levels. Clin Endocrinol (Oxf). 2010;73:413–20.

24. Alamdari DH, Moghaddam AB, Amini S, Keramati MR, Zarmehri AM, Alamdari AH, et al. Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. Eur J Pharmacol. 2020;885:173494.

25. Navarro-González JA, García-Benayas C, Arenas J. Semiautomated measurement of nitrate in biological fluids. Clin Chem. 1998;44:679–81.

26. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruning H, et al. The Sepsis-related Organ Failure Assessment (SOFA) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22:707–10.

27. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.

28. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801–10.

29. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307:2526–33.

30. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–45.

31. Wong HR, Carcillo JA, Burckart G, Kaplan SS. Nitric oxide production in critically ill patients. Arch Dis Child. 1996;74:482–9.

32. Abate BB, Kassie AM, Kassaw MW, Arajie TG, Masresha SA. Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. BMJ Open. 2020;10:e040129.

33. El-Awady MS, Nader MA, Sharawy MH. The inhibition of inducible nitric oxide synthase and oxidative stress by agmatine attenuates vascular dysfunction in rat acute endotoxemic model. Environ Toxicol Pharmacol. 2017;55:74–80.

34. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis thrombosis, and angiogenesis in covid-19. N Engl J Med. 2020;383:120–8.

35. Grimm EA, Sikora AG, Ekmeckcioglu S. Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clin Cancer Res. 2013;19:5557–63.

36. Bocca C, Novo E, Miglietta A, Parola M. Angiogenesis and fibrogenesis in chronic liver diseases. Cell Mol Gastroenterol Hepatol. 2015;1:477–88.

37. Hu LS, George J, Wang JH. Current concepts on the role of nitric oxide in portal hypertension. World J Gastroenterol. 2013;19:1707–17.

38. Yamashikii H. Blood nitrate and nitrite modulating nitric oxide bioavailability: Potential therapeutic functions in COVID-19. Nitric Oxide. 2020;103:29–30.

39. Ignarro LJ. Inhaled NO and COVID-19. Br J Pharmacol. 2020;177:3848–9.